Amit D. Munshi, insider at Arena Pharmaceuticals

Amit D. Munshi Insider Information

Amit D. Munshi has served as a member of Arena Pharmaceuticals’ Board of Directors since June 2016, and as our President and Chief Executive Officer since May 2016. Previously, Mr. Munshi served as President and Chief Executive Officer of Epirus Biopharmaceuticals, Inc. and Percivia LLC, a biotechnology company (sold to JNJ).  Prior to Epirus and Percivia, Mr. Munshi was a co-founder and served as Chief Business Officer of Kythera Biopharmaceuticals, Inc., from 2005 to 2010, (sold $2.1B to AGN) and held multiple leadership positions at Amgen Inc. from 1997 to 2005, including General Manager, Nephrology Europe. Mr. Munshi holds a B.S. in Economics and a B.A. in History from the University of California, Riverside, and an M.B.A. from the Peter F. Drucker School of Management at Claremont Graduate University. Mr. Munshi has 30 years of global biopharmaceutical industry experience in executive management, business development, product development and portfolio management. Mr. Munshi currently serves on the boards of  Pulmatrix, Inc. (Nasdaq: PULM), Enterprise Therapeutics Ltd, and Galecto, Inc.

What is Amit D. Munshi's net worth?

The estimated net worth of Amit D. Munshi is at least $3.95 million as of August 16th, 2021. Mr. Munshi owns 39,550 shares of Arena Pharmaceuticals stock worth more than $3,954,605 as of August 16th. This net worth evaluation does not reflect any other investments that Mr. Munshi may own. Additionally, Mr. Munshi receives an annual salary of $1,220,000.00 as CEO at Arena Pharmaceuticals. Learn More about Amit D. Munshi's net worth.

How old is Amit D. Munshi?

Mr. Munshi is currently 54 years old. There are 1 older executives and no younger executives at Arena Pharmaceuticals. Learn More on Amit D. Munshi's age.

What is Amit D. Munshi's salary?

As the CEO of Arena Pharmaceuticals, Inc., Mr. Munshi earned a total compensation package of $6,896,609.00 in 2020. Mr. Munshi earned a salary of $687,500.00, options awards of $5,676,561.00, non-equity compensation of $514,206.00, and other compensation of $18,342.00. Learn More on Amit D. Munshi's salary.

How do I contact Amit D. Munshi?

The corporate mailing address for Mr. Munshi and other Arena Pharmaceuticals executives is 6154 Nancy Ridge Drive, San Diego CA, 92121. Arena Pharmaceuticals can also be reached via phone at (858) 453-7200 and via email at [email protected] Learn More on Amit D. Munshi's contact information.

Has Amit D. Munshi been buying or selling shares of Arena Pharmaceuticals?

Amit D. Munshi has not been actively trading shares of Arena Pharmaceuticals over the course of the past ninety days. Most recently, on Monday, August 16th, Amit Munshi bought 1,000 shares of Arena Pharmaceuticals stock. The stock was acquired at an average cost of $48.19 per share, with a total value of $48,190.00. Following the completion of the transaction, the chief executive officer now directly owns 39,550 shares of the company's stock, valued at $1,905,914.50. Learn More on Amit D. Munshi's trading history.

Who are Arena Pharmaceuticals' active insiders?

Arena Pharmaceuticals' insider roster includes Vincent Aurentz (VP), Christopher Cabell (CMO), Jayson Dallas (Director), Robert Lisicki (EVP), Amit Munshi (CEO), Tina Nova (Director), Manmeet Soni (Director), and Manmeet Soni (Director). Learn More on Arena Pharmaceuticals' active insiders.

Are insiders buying or selling shares of Arena Pharmaceuticals?

During the last year, Arena Pharmaceuticals insiders bought shares 1 times. They purchased a total of 1,000 shares worth more than $48,190.00. The most recent insider tranaction occured on August, 16th when CEO Amit Munshi bought 1,000 shares worth more than $48,190.00. Insiders at Arena Pharmaceuticals own 2.4 % of the company. Learn More about insider trades at Arena Pharmaceuticals.

Information on this page was last updated on 8/16/2021.

Amit D. Munshi Insider Trading History at Arena Pharmaceuticals

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
8/16/2021Buy1,000$48.19$48,190.0039,550View SEC Filing Icon  
8/12/2021Buy1,000$50.41$50,410.00View SEC Filing Icon  
8/10/2021Buy1,000$52.91$52,910.00View SEC Filing Icon  
1/19/2021Sell50,000$80.14$4,007,000.0057,750View SEC Filing Icon  
1/15/2021Sell50,000$80.24$4,012,000.0057,750View SEC Filing Icon  
1/12/2021Sell14,877$75.12$1,117,560.2420,627View SEC Filing Icon  
12/8/2020Sell6,517$70.00$456,190.007,750View SEC Filing Icon  
8/31/2020Sell50,000$70.10$3,505,000.0057,750View SEC Filing Icon  
8/28/2020Sell50,000$70.00$3,500,000.0057,750View SEC Filing Icon  
6/2/2020Sell50,000$65.00$3,250,000.0057,750View SEC Filing Icon  
5/22/2020Sell34,800$58.12$2,022,576.0057,750View SEC Filing Icon  
2/13/2020Sell15,200$55.00$836,000.0022,950View SEC Filing Icon  
5/12/2017Buy25,000$1.19$29,750.0076,875View SEC Filing Icon  
4/26/2017Buy50,000$1.41$70,500.001,875View SEC Filing Icon  
See Full Table

Amit D. Munshi Buying and Selling Activity at Arena Pharmaceuticals

This chart shows Amit Munshi's buying and selling at Arena Pharmaceuticals by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Arena Pharmaceuticals Company Overview

Arena Pharmaceuticals logo
Arena Pharmaceuticals, Inc., a biopharmaceutical company, focuses on providing novel medicines with pharmacology and pharmacokinetics to patients worldwide. The company's investigational clinical programs include Etrasimod (APD334) that is in Phase III clinical trial for ulcerative colitis, Phase IIb/III clinical trial for Crohn's disease, Phase II clinical trial for alopecia areata, Phase III clinical trial for atopic dermatitis, and Phase IIb clinical trial for eosinophilic esophagitis; Olorinab (APD371), which is in Phase IIb clinical trial for the treatment of abdominal pain associated with irritable bowel syndrome; APD418 that is in Phase II clinical trial for acute heart failure; and Temanogrel for coronary microvascular obstruction that is in Phase II clinical trial. It also develops ralinepag (APD811), which is in Phase III clinical trial for pulmonary arterial hypertension. The company has collaboration agreements with United Therapeutics Corporation; Everest Medicines Limited; Eisai Co., Ltd. and Eisai Inc.; Boehringer Ingelheim International GmbH; Beacon Discovery, Inc.; and Aristea Therapeutics, Inc. Arena Pharmaceuticals, Inc. was incorporated in 1997 and is based in Park City, Utah. As of March 11, 2022, Arena Pharmaceuticals, Inc. operates as a subsidiary of Pfizer Inc.
Read More

Today's Range

Now: $99.99
Low: $99.99
High: $99.99

50 Day Range

MA: $97.65
Low: $93.13
High: $99.99

2 Week Range

Now: $99.99
Low: $45.50
High: $100.00

Volume

107 shs

Average Volume

1,561,326 shs

Market Capitalization

$6.17 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.55